EXACT Therapeutics AS: New option program and receipt of share options by primary insiders

24 November 2025: EXACT Therapeutics AS ("EXACT Tx" or the "Company") announces that the Company as of today has introduced a new long-term incentive program in the form of award of share options, each giving the right to purchase one share in the Company at a strike price to be determined by the board of directors of the Company, and with settlement in either shares in the Company or cash (the "New Incentive Program"). The options will vest in tranches conditional upon the participants continuous positions with the group, and are exercisable in designated exercise windows, with the intention of following, inter alia, the end of the quarter after the vesting periods. The Company wil issue a total of 1 069 643 options under the New Incentive Program. The New Incentive Program replaces the current incentive program of the Company (the "Current Incentive Program"). Thus, options held by certain primary insiders of the Company under the Current Incentive Program will lapse accordingly, while new options will be awarded to the respective participants, including primary insiders, as further set out in the attached notifications of trade. This information is subject to the disclosure requirements in article 19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian Securities Trading Act. For more information, please contact: Per Walday, CEO EXACT Therapeutics Email per.walday@exact-tx.com About EXACT-Tx: EXACT-Tx is a clinical-stage precision medicine company utilizing the power of ultrasound and microbubbles to enable targeted drug delivery in oncology. Acoustic Cluster Therapy (ACT®) follows a unique approach and may be applied to a wide range of therapeutic agents across a multitude of indications including within oncology (chemotherapy, immunotherapy) and brain diseases. www.exact-tx.com